Samil Pharmaceutical Co.,Ltd (KRX:000520)

Market Cap	182.79B -22.8%
Revenue (ttm)	210.25B -4.3%
Net Income	-34.66B
EPS	-1,633.00
Shares Out	21.23M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	93,239
Average Volume	236,299
Open	8,610.00
Previous Close	8,610.00
Day's Range	8,440.00 - 8,660.00
52-Week Range	8,430.00 - 13,300.00
Beta	0.43
RSI	33.53
Earnings Date	May 21, 2026

About KRX:000520

Samil Pharmaceutical Co.,Ltd engages in the manufacture and sale of pharmaceuticals in South Korea. It offers general medicines, including Tiersil Once, EYE2O mini eye drops, and Optagent ophthalmic drops; medical devices; secret spotpatch quasi-drugs, and roll away products. The company also provides specialty medicines, such as Hycell solutions; Curelen, Ocufridine, Ocumetholone, Ocucyclo, Ocuhomapine, Ocucarpine, Allerfen, Optanac, Forus, Eymox, Cifex, and Ocuracin ophthalmic drops; and Herpecid, Forus, and Ocurasin ophthalmic ointments. Sam...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1947
• Employees: 583
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 000520

Financial Performance

In 2025, KRX:000520's revenue was 210.25 billion, a decrease of -4.30% compared to the previous year's 219.70 billion. Losses were -34.66 billion, 515.8% more than in 2024.